Good Tokens Advances Transparent Digital Infrastructure for Social and Humanitarian Use

Singapore, Singapore–(Newsfile Corp. – January 7, 2026) – Good Tokens, the nonprofit initiative of KaJ Labs, announced continued advancements in its transparent digital infrastructure designed to support social and humanitarian use cases worldwide. Through GoodTokens.org, the initiative applies blockchain technology and artificial intelligence to build accountable, efficient systems that enhance trust, coordination, and measurable outcomes […]

Technip Energies awarded two large contracts by BPCL for new units at Bina and Mumbai refineries in India

(Paris:TE),(Euronext Amsterdam:TE), Technip Energies (PARIS:TE) has been awarded two large(1) contracts by Bharat Petroleum Corporation Limited (BPCL) for key projects at its Bina refinery in Madhya Pradesh and Mumbai refinery in Maharashtra, India. The first contract covers Engineering, Procurement, Construction and Commissioning (EPCC) for new polypropylene and Butene-1 units at the Bina refinery in Madhya

Technip Energies awarded two large contracts by BPCL for new units at Bina and Mumbai refineries in India

Technip Energies awarded two large contracts by BPCL for new units at Bina and Mumbai refineries in India GlobeNewswire January 07, 2026 Technip Energies (PARIS:TE) has been awarded two large(1) contracts by Bharat Petroleum Corporation Limited (BPCL) for key projects at its Bina refinery in Madhya Pradesh and Mumbai refinery in Maharashtra, India. The first

Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM – NTX-253 for Schizophrenia

Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM – NTX-253 for Schizophrenia GlobeNewswire January 07, 2026 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 7, 2026 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric

Trends and Policies in Europe Plastic Packaging Market 2025-35

Trends and Policies in Europe Plastic Packaging Market 2025-35 As detailed in the latest report by Towards Packaging, the Europe plastic packaging market is forecast to grow from USD 116.87 billion in 2026 to about USD 189.22 billion by 2034, at a CAGR of 5.5% between 2025 and 2034. GlobeNewswire January 07, 2026 Ottawa, Jan.

Tradomatix Launches Technology Platform Connecting Trading Capital, Quant Talent, and Machine Intelligence

Tradomatix Launches Technology Platform Connecting Trading Capital, Quant Talent, and Machine Intelligence New global infrastructure enables hedge funds, quantitative traders, and AI systems to operate within unified trading ecosystem GlobeNewswire January 07, 2026 Singapore, Jan. 07, 2026 (GLOBE NEWSWIRE) — Tradomatix today announced the launch of its global trading technology platform, creating the infrastructure layer

WELT Unveils the World’s First “AI-Combo Drug” at CES 2026

Turning Any Medication into a Precision AI-Combo Drug through Simple QR-Code Integration LAS VEGAS, NV / ACCESS Newswire / January 7, 2026 / WELT, the Samsung spin-off digitalâ?’pharmaceutical company behind the KFDAâ?’approved and CEâ?’certified insomnia Digital Therapeutics ‘SleepQ’, announced today that it has been named a CES 2026 Innovation Awards Honoree for its groundbreaking AI

Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering

(NASDAQ:PRAX), BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the pricing of its underwritten public offering of 2,212,000 shares of its common stock at a

Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering

Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering GlobeNewswire January 07, 2026 BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the pricing

Scroll to Top